10X Genomics, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US88025U1097
USD
18.15
0.21 (1.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About 10X Genomics, Inc. stock-summary
stock-summary
10X Genomics, Inc.
Pharmaceuticals & Biotechnology
10x Genomics, Inc. is a life science technology company. The Company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. The Company’s product consists of chromium single cell gene expression solution, cell immune profiling solution, cell copy number variation (CNV) solution, Cell assay for transposase accessible chromatin (ATAC) solution. The Company’s Chromium platform enables analysis of individual biological components, such as up to millions of single cells. Its Visium platform is designed to identify where biological components are located and how they are arranged with respect to each other. Its molecular assays are used with its Chromium platform, and with its planned Visium platform, to provide sensitive and robust biochemistries that convert minute amounts of biological analytes into detectable signals.
Company Coordinates stock-summary
Company Details
6230 Stoneridge Mall Road , PLEASANTON CA : 94588
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 68 Schemes (54.29%)

Foreign Institutions

Held by 167 Foreign Institutions (29.02%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. John Stuelpnagel
Independent Chairman of the Board
Dr. Benjamin Hindson
President, Co-Founder, Chief Scientific Officer, Director
Mr. Serge Saxonov
Chief Executive Officer, Co-Founder, Director
Mr. Sridhar Kosaraju
Independent Director
Dr. Mathai Mammen
Independent Director
Ms. Kimberly Popovits
Independent Director
Dr. Bryan Roberts
Independent Director
Dr. Shehnaaz Suliman
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
173 Million
(Quarterly Results - Jun 2025)
Net Profit:
35 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,734 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.57

stock-summary
Return on Equity

-17.00%

stock-summary
Price to Book

2.24